150 related articles for article (PubMed ID: 16147992)
1. Analysis of BCL6-interacting proteins by tandem mass spectrometry.
Miles RR; Crockett DK; Lim MS; Elenitoba-Johnson KS
Mol Cell Proteomics; 2005 Dec; 4(12):1898-909. PubMed ID: 16147992
[TBL] [Abstract][Full Text] [Related]
2. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
3. POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.
Pero R; Palmieri D; Angrisano T; Valentino T; Federico A; Franco R; Lembo F; Klein-Szanto AJ; Del Vecchio L; Montanaro D; Keller S; Arra C; Papadopoulou V; Wagner SD; Croce CM; Fusco A; Chiariotti L; Fedele M
J Biol Chem; 2012 May; 287(22):18308-17. PubMed ID: 22493480
[TBL] [Abstract][Full Text] [Related]
4. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
5. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
6. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
7. The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.
Baron BW; Baron RM; Baron JM
Biochim Biophys Acta; 2015 May; 1852(5):742-8. PubMed ID: 25557390
[TBL] [Abstract][Full Text] [Related]
8. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.
Liu H; Ippolito GC; Wall JK; Niu T; Probst L; Lee BS; Pulford K; Banham AH; Stockwin L; Shaffer AL; Staudt LM; Das C; Dyer MJ; Tucker PW
Mol Cancer; 2006 May; 5():18. PubMed ID: 16704730
[TBL] [Abstract][Full Text] [Related]
9. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
10. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
Basso K; Dalla-Favera R
Adv Immunol; 2010; 105():193-210. PubMed ID: 20510734
[TBL] [Abstract][Full Text] [Related]
11. Internal deletions within the BCL6 gene in B-cell non-Hodgkin's lymphoma.
Nakamura Y
Leuk Lymphoma; 2000 Aug; 38(5-6):505-12. PubMed ID: 10953971
[TBL] [Abstract][Full Text] [Related]
12. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
13. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.
Bertolo C; Roa S; Sagardoy A; Mena-Varas M; Robles EF; Martinez-Ferrandis JI; Sagaert X; Tousseyn T; Orta A; Lossos IS; Amar S; Natkunam Y; Briones J; Melnick A; Malumbres R; Martinez-Climent JA
Br J Haematol; 2013 Sep; 162(5):621-30. PubMed ID: 23795761
[TBL] [Abstract][Full Text] [Related]
14. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
15. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
16. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
17. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation.
Chen W; Iida S; Louie DC; Dalla-Favera R; Chaganti RS
Blood; 1998 Jan; 91(2):603-7. PubMed ID: 9427715
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of BCL6 during germinal center B cell development.
Huang C; Melnick A
Sci China Life Sci; 2015 Dec; 58(12):1226-32. PubMed ID: 26566802
[TBL] [Abstract][Full Text] [Related]
19. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
20. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.
Lemercier C; Brocard MP; Puvion-Dutilleul F; Kao HY; Albagli O; Khochbin S
J Biol Chem; 2002 Jun; 277(24):22045-52. PubMed ID: 11929873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
